---
title: "Lakewood-Amedex Biotherapeutics, Inc. (LABT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LABT.US.md"
symbol: "LABT.US"
name: "Lakewood-Amedex Biotherapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-25T16:46:42.062Z"
locales:
  - [en](https://longbridge.com/en/quote/LABT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LABT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LABT.US.md)
---

# Lakewood-Amedex Biotherapeutics, Inc. (LABT.US)

## Company Overview

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin® class, a novel class of antimicrobial agents that fight infections by disrupting microbial membranes. It develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [lakewoodamedex.com](https://lakewoodamedex.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LABT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LABT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LABT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LABT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**